Beneficial effects of a switch to a lopinavir/ritonavir-containing regimen for patients with partial or no immune reconstitution with highly active antiretroviral therapy despite complete viral suppression

AIDS Research and Human Retroviruses

Volumn 27, Issue 6, 2011, Pages 659-667

  Pitrak, D L ^a   Estes, R ^a   Novak, R M ^b   Linnares Diaz, M ^b   Tschampa, J M ^c  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOPINAVIR PLUS RITONAVIR; VIRUS RNA;

ADULT; APOPTOSIS; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EX VIVO STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MALE; MEMORY CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE SUBPOPULATION; TREATMENT RESPONSE; VIRUS DETECTION; VIRUS INHIBITION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PYRIMIDINONES; RITONAVIR; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 79957597321     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2010.0230     Document Type: Article

References (47)

1. Autran B, Carcelain G, Li TS, et al.: Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced disease. Science 1997;277:112-116 (Pubitemid 27450659)
2. Dronda F, Moreno S, Moreno A, et al.: Long-term outcomes among antiretroviral-naive human immunodeficiency virusinfected patients with small increases in CD4+ cell counts after successful virological suppression. Clin Infect Dis 2002;35:1005-1009 (Pubitemid 35178319)
3. Moore DM, Hogg RS, Yip B, et al.: Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. JAIDS 2005;40(3):288-293 (Pubitemid 41533068)
4. Tan R, Westfall AO, Willig JH, et al.: Clinical outcome of HIV-infected antiretroviral naïve patients with discordant immunologic and virologic responses to highly active antiretroviral therapy. JAIDS 2008;47(5):553-558 (Pubitemid 351442024)
5. Chavan SJ, Tamma SL, Kaplan M, et al.: Reduction in T cell apoptosis in patients with HIV disease following antiretroviral therapy. Clin Immunol 1999;93(1):24-33 (Pubitemid 29459959)
6. Roger PM, Breittmayer JP, Arlotto C, et al.: Highly active anti-retroviral therapy (HAART) is associated with a lower level of CD4+ T cell apoptosis in HIV-infected patients. Clin Exp Immunol 1999;118(3):412-416
7. Sloand EM, Kumar PN, et al.: Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo. Blood 1999;94(3): 1021-1027 (Pubitemid 29361834)
8. Panel on Antiretroviral Guidelines for Adult and Adolescents: Guidelines for the use of antiretroviral agents in HIV- 1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009
9. Barreiro P, Soriano V, Casas E, et al.: Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides. AIDS 2002;16:245-249 (Pubitemid 34118572)
10. Deeks SG, Barbour JD, Grant RM, et al.: Duration and predictors of CD4 T cell gain in patients who continue combination therapy despite detectable plasma viremia. AIDS 2002;16(2):201-207 (Pubitemid 34118567)
11. Bartlett JA, Fath MJ, DeMasi R, et al.: An updated systematic review of triple combination therapy in antiretroviral-naive HIV-infected patients. AIDS 2006;20:2051-2064 (Pubitemid 44611058)
12. Murphy RL, Da Silva BA, Hicks CB, et al.: Seven-year efficacy of a lopinavir/ritonavir based regimen in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials 2008;9(1):1-10 (Pubitemid 351214236)
13. Moore RD and Keruly JC: CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007;44:441-446 (Pubitemid 46147630)
14. Gras L, Kesselring AM, Griffin JT, et al., on Behalf of the ATHENA, Netherlands National Observational Cohort Study: CD4cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr 2007;45(2):183-192 (Pubitemid 46869811)
15. Nicoletti I, Migliorati G, Pagliacci F, et al.: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271-279
16. Patterson BK, McCallister S, Schutz M, et al.: Persistence of intracellular HIV-1 mRNA correlates with HIV-1 specific immune responses in infected subjects on stable HAART. AIDS 2001;15:1635-1641 (Pubitemid 32923062)
17. Anastos K, Barron Y, Cohen M, et al.: The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med 2004;140:256-264
18. Kitchen CM, Kitchen SG, Dubin JA, et al.: Initial virological and immunologic response to highly active antiretroviral therapy predicts long-term clinical outcome. Clin Infect Dis 2001;33:466-472 (Pubitemid 32709577)
19. Monforte Ad'A, Tesotri V, Adonri F, et al.: CD4 cell counts at the third month of HAART may predict clinical failure. AIDS 1999;13:1669-1676
20. Brabar S, Le Moing V, Goujard C, et al.: Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000;133:401-410
21. Florence E, Lundgren J, Dreezen C, et al.: Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med 2003;4:255-262 (Pubitemid 36949882)
22. Kaufmann GR, Perrin L, Pantaleo G, et al.: CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: The Swiss Cohort Study. Arch Intern Med 2003;163:2187-2195 (Pubitemid 37248783)
23. Weber R, Sabin CA, Friis-Moller N, et al.:, for the Data Collection on Adverse Events of Anti-HIV Drugs Study Group: Liver-related deaths in persons infected with the human immunodeficiency virus. The D:A:D Study. Arch Intern Med 2006;166(15):1632-1641 (Pubitemid 44232373)
24. Le Moing V, Thiebaut R, Chene G, et al:, for the ANRS CO8 (APROCO/COPILOTE) Study Group: Long-term evaluation of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs (Pubitemid 46915686)
25. 3 reach the same mortality rates as general population: APROCO and Aquitaine cohorts, France. 10th European AIDS Conference. Dublin, Ireland, 2005 (Poster PE184/8).
26. Giorgi JV, Hutlin LE, McKeating JA, et al.: Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associate d with T lymphocyte activation than with plasma burden or virus chemokine receptor usage. J Infect Dis 1999;179:859-870 (Pubitemid 29159331)
27. Carbone J, Gil J, Benito JM, et al.: Increased levels of activated subsets of CD4+ T cells add to the prognostic value of low CD4+ counts in a cohort of HIV-infected drug users. AIDS 2000;14:2823-2829 (Pubitemid 32042745)
28. Anthony KB, Yoder C, Metcalf JA, et al.: Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4T cell activation and turnover. JAIDS 2003;33: 125-133 (Pubitemid 36793144)
29. Hunt PW, Martin JN, Sinclair E, et al.: T cell activation is associated with lower CD4+ T cells gains in human immunodeficiency virus-infected patients with sustained suppression during antiretroviral therapy. J Infect Dis 2003; 187:1534-1543 (Pubitemid 36578959)
30. Haas D, Geraghty D, Andersen J, et al.: Immunogenetics and immune reconstitution during potent antiretroviral therapy: NWCS 233, an analysis of AACTG protocol A5001 3rd IAS Conference on HIV Pathogenesis and Treatment. 2005, July 24-27, Rio de Janeiro. Abstract MoOa0303
31. Pitrak DL, Bolanos J, Hershow R, et al.: Discordant CD4+ T lymphocyte responses to antiretroviral therapy for HIV infection are associated with ex vivo apoptosis. AIDS 2001; 15(10):1317-1391
32. Marchetti G, Gori A, Casabianca A, et al.: Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. AIDS 2006:20(13):11727-11736
33. Douek DC, McFarland RD, Keiser PH, et al.: Changes in thymic function with age and during the treatment of HIV infection. Nature 1998;396(6712):690- 695 (Pubitemid 29003949)
34. Smith KY, Valdez H, Landay A, et al., and the ACTG 374 Protocol Team: Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy. J Infect Dis 2000;181(1):141-147 (Pubitemid 30049042)
35. Kolte L, Dreves AM, Ersboll AK, et al.: Association between larger thymus size and higher thymic output in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. J Infect Dis 2002;185(11):1578-1585 (Pubitemid 34587519)
36. Arno A, Ruiz L, Juan M, et al.: Efficacy of low-dose subcutaneous interkeukin-2 to treat advanced human immunodeficiency virus type 1 in patients with
37. Katlama C, Carcelain G, Duvivier C, et al.: Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: The ILSTIM study-ANRS082 AIDS 2002; 16(15):2027-2034
38. INSIGHT-ESPRIT Study Group; SILCAAT Scientific Committee, Abrams D, Levy Y, Losso MH, et al.: Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009; 361(16):1548-1549
39. Burton CT, Mela G, Rosignoli G, et al.: Immune modulation and reconstitution of HIV-1-specific responses: Novel approaches and strategies. Curr Med Chem 2006;13:3203-3211 (Pubitemid 44680864)
40. Hammer S, Bassett R, Fischl M, et al., for the ACTG 372A Study Team: Randomized, placebo-controlled trial of abacavir intensification in HIV-1 infected adults with plasma HIV RNA <500 copies/mL 11th Conference on Retroviruses and Opportunistic Infections for the ACTG 372A Study Team February 8-11 2004 San Francisco, CA. Abstract 56
41. Mocroft A, Phillips AN, Lederberger B, et al.: Relationship between antiretrovirals used as part of a HAART regimen and CD4cell count increases in patients with suppressed viremia. AIDS 2006;20(8):1141-1150 (Pubitemid 43786102)
42. Riddler SA, Haubrich R, DiRienzo AG, et al.: Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008;358(20):2095-2106 (Pubitemid 351679596)
43. Badley AD: In vitro and in vivo effects of HIV protease inhibitors on apoptosis. Cell Death Differ 2005;(Suppl 1):924-931 (Pubitemid 41030607)
44. Phenix BN, Lum JJ, Nie Z, et al.: Antiapoptotic mechanism of HIV protease inhibitors: Preventing mitochondrial transmembrane potential loss. Blood 2001;98:1078-1085
45. Weaver JGR, Tarze A, Moffat, et al.: Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor. J Clin Invest 2005;115(7):1828-1838 (Pubitemid 40979721)
46. Vlahakis SR, Bren GD, Algeciras-Schimnich A, et al.: Flying in the face of resistance: Antiviral-independent benefit of HIV protease inhibitors on T-call survival. Clin Pharmacol Ther 2007;82(3):294-299 (Pubitemid 47258465)
47. Rizza SA and Badley AD: HIV protease inhibitors impact on apoptosis. Med Chem 2008;41(1):75-79 (Pubitemid 351320923)